In vivo applications and toxicities of AAV-based gene therapies in rare diseases

Qian Zhao, Huifang Peng, Yujin Ma, Huijun Yuan, Hongwei� JiangOrphanet 2025 · DOI

Abstract

Adeno-associated virus (AAV), renowned for its exceptionally low pathogenicity and significant efficacy in clinical gene therapy, has emerged as a leading delivery vector in the field of gene therapy. AAV can achieve stable gene expression in various tissues, which has made it a promising treatment for genetic disorders. To date, eight AAV-based gene therapies have been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). This review summarizes clinical trials of AAV gene therapies for rare diseases, including ophthalmic diseases, nervous system disorders, hematological diseases, neuromuscular diseases, and lysosomal storage diseases. We also explore potential side effects and toxicities associated with AAV therapies. Our objective is to provide valuable insights for researchers and clinicians working on AAV-based therapies, helping improve the safety and effectiveness of these treatments.

Introduction

Rare genetic diseases, often caused by mutations in a single gene, present ideal targets for gene therapy. Adeno-associated virus (AAV) has become the "gold standard" for delivery due to its low pathogenicity and ability to provide long-lasting gene expression. Currently, eight AAV-based therapies have received regulatory approval from the FDA and EMA. However, the field faces a significant challenge: the "delivery vs. toxicity" paradox. Achieving therapeutic efficacy in systemic diseases often requires high viral doses, which can trigger severe immune responses and organ damage. This paper synthesizes the current landscape of AAV therapies, focusing on delivery strategies, clinical successes, and emerging safety hurdles.

Manufacturing and Delivery Methods

The clinical success of AAV therapy depends heavily on efficient manufacturing and precise delivery. There are four primary production platforms currently in use: stable transfection (HeLa cells), triple-plasmid co-transfection (HEK293 cells), baculovirus systems (Sf9 insect cells), and recombinant herpes simplex virus (rHSV) systems.

Overview of the four primary AAV manufacturing platforms: stable transfection, triple-plasmid co-transfection, baculovirus systems, and recombinant herpes simplex virus systems.

Beyond manufacturing, the route of administration is critical. There is a growing shift from systemic intravenous (IV) injections toward localized delivery—such as subretinal, intraparenchymal, or intracisternal magna injections. Localized delivery maximizes efficacy in target tissues like the eye or brain while minimizing systemic exposure and the associated risk of immune "storms." Furthermore, selecting the appropriate AAV serotype (1 through 13) allows researchers to exploit natural tissue tropisms, targeting specific organs like the heart or liver more effectively.

Clinical Applications and Efficacy

AAV therapies have demonstrated transformative results in several rare disease categories:

  • Ophthalmic Diseases: Luxturna (for LCA2) has shown over a 100-fold improvement in vision, with benefits persisting for over four years.
  • Hematological Diseases: Hemgenix (for Hemophilia B) reduced annualized bleeding rates by 71% in Phase III trials.
  • Neuromuscular Disorders: Zolgensma (for SMA1) has dramatically altered the disease's natural history, with 91-97% of treated infants surviving without permanent ventilation at 14 months.

Safety and Toxicities

Despite clinical successes, significant safety concerns remain. High-dose systemic AAV administration is frequently associated with hepatotoxicity; in Hemophilia A trials, over 85% of participants experienced elevated liver enzymes, though most were manageable with steroids. A more severe, albeit rarer, complication is Thrombotic Microangiopathy (TMA), which has led to fatalities in some SMA patients.

A critical emerging concern is Dorsal Root Ganglion (DRG) toxicity, where high-dose AAV causes nerve cell damage. Researchers are developing innovative solutions, such as incorporating microRNA-183 targets to selectively silence the transgene in nerve cells. Additionally, pre-existing immunity to AAV in the general population remains a major barrier, excluding many patients from treatment and necessitating the development of "stealth" capsids.

Limitations and Future Outlook

AAV vectors are limited by a packaging capacity of approximately 4.7 kilobases, which precludes the delivery of large genes like full-length dystrophin. Furthermore, while gene expression is stable, it may diminish over time in dividing cells, such as those in a growing child's liver.

The future of the field lies in "Next-Gen" AAVs. This includes rationally designed synthetic capsids with enhanced tissue targeting and reduced immunogenicity, alongside the refinement of preemptive immunosuppression protocols to improve the safety profile of high-dose systemic therapies.

Summary updated

Abstract

Adeno-associated virus (AAV), renowned for its exceptionally low pathogenicity and significant efficacy in clinical gene therapy, has emerged as a leading delivery vector in the field of gene therapy. AAV can achieve stable gene expression in various tissues, which has made it a promising treatment for genetic disorders. To date, eight AAV-based gene therapies have been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). This review summarizes clinical trials of AAV gene therapies for rare diseases, including ophthalmic diseases, nervous system disorders, hematological diseases, neuromuscular diseases, lysosomal storage diseases. We also explore potential side effects and toxicities associated with AAV therapies. Our objective is to provide valuable insights for researchers and clinicians working on AAV-based therapies, helping improve the safety and effectiveness of these treatments.
BibTeX
@inproceedings{zhao2025vivo,
  author = {Qian Zhao and Huifang Peng and Yujin Ma and Huijun Yuan and Hongwei� Jiang},
  title = {{In vivo applications and toxicities of AAV-based gene therapies in rare diseases}},
  booktitle = {Orphanet},
  year = {2025},
  doi = {10.1186/s13023-025-03893-z},
}
Figure